Literature DB >> 12794118

Potentiation of a tumor cell susceptibility to autologous CTL killing by restoration of wild-type p53 function.

Jérôme Thiery1, Guillaume Dorothée, Hedi Haddada, Hamid Echchakir, Catherine Richon, Rodica Stancou, Isabelle Vergnon, Jean Benard, Fathia Mami-Chouaib, Salem Chouaib.   

Abstract

Inactivation of p53 has been implicated in many types of tumors particularly in non-small cell lung carcinoma, one of the most common cancers in which p53 mutation has been frequently identified. The aim of this study was to investigate the influence of p53 status on the regulation of tumor susceptibility to specific CTL-mediated cell death. For this purpose, we used a cytotoxic T lymphocyte clone, Heu127, able to lyse the human autologous lung carcinoma cell line, IGR-Heu, in a HLA-A2-restricted manner. Direct genomic DNA sequencing revealed that IGR-Heu expresses a mutated p53 at codon 132 of the exon 5 which results in the loss of p53 capacity to induce the expression of the p53-regulated gene product p21(waf/CIP1). Initial experiments demonstrated that IGR-Heu was resistant to Fas, TNF, and TRAIL apoptotic pathways. This correlated with the lack of p55 TNFRI, Fas, DR4, and DR5 expression. The effect of wild-type (wt) p53 restoration on the sensitization of IGR-Heu to autologous CTL clone lysis was investigated following infection of the tumor cell line with a recombinant adenovirus encoding the wt p53 (Adwtp53). We demonstrate that the restoration of wt p53 expression and function resulted in a significant potentiation of target cell susceptibility to CTL-mediated lysis. The wt p53-induced optimization of tumor cell killing by specific CTL involves at least in part Fas-mediated pathway via induction of CD95 expression by tumor cells but does not appear to interfere with granzyme B cytotoxic pathway.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12794118     DOI: 10.4049/jimmunol.170.12.5919

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  6 in total

Review 1.  Resistance to anticancer immunity in cancer patients: potential strategies to reverse resistance.

Authors:  B Bonavida; S Chouaib
Journal:  Ann Oncol       Date:  2017-03-01       Impact factor: 32.976

Review 2.  DNA vaccines, electroporation and their applications in cancer treatment.

Authors:  Si-Hyeong Lee; Sayyed Nilofar Danishmalik; Jeong-Im Sin
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  hSMG-1 is a granzyme B-associated stress-responsive protein kinase.

Authors:  Franck Meslin; Ahmed Hamaï; Bernhard Mlecnik; Filippo Rosselli; Catherine Richon; Abdelali Jalil; Gregory Wemhoff; Jerome Thiery; Jerome Galon; Salem Chouaib
Journal:  J Mol Med (Berl)       Date:  2011-02-08       Impact factor: 4.599

4.  Computational prediction and experimental assessment of an HLA-A*0201-restricted cytotoxic T lymphocyte epitope from neutral endopeptidase.

Authors:  Jingbo Zhang; Zhengcai Jia; Zhihua Lin; Jingyi Li; Xiaolan Fu; Yunjian Huang; Jinghong Zhao; Ling Nie; Weiping Hou; Fahuan Yuan; Yuzhang Wu
Journal:  Immunol Res       Date:  2012-06       Impact factor: 2.829

5.  Calcarea carbonica induces apoptosis in cancer cells in p53-dependent manner via an immuno-modulatory circuit.

Authors:  Shilpi Saha; Dewan Md Sakib Hossain; Shravanti Mukherjee; Suchismita Mohanty; Minakshi Mazumdar; Sanhita Mukherjee; Uttam K Ghosh; Chaturbhuj Nayek; Chinta Raveendar; Anil Khurana; Rathin Chakrabarty; Gaurisankar Sa; Tanya Das
Journal:  BMC Complement Altern Med       Date:  2013-09-21       Impact factor: 3.659

Review 6.  The Role of p53 Dysfunction in Colorectal Cancer and Its Implication for Therapy.

Authors:  Maurice Michel; Leonard Kaps; Annett Maderer; Peter R Galle; Markus Moehler
Journal:  Cancers (Basel)       Date:  2021-05-11       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.